| P50 | author | Stephen R Durham | Q90028025 |
| P2093 | author name string | M H Shamji | |
| P2860 | cites work | Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. | Q51996007 |
| | Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. | Q52697877 |
| | Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. | Q52940754 |
| | Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. | Q54584880 |
| | Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 |
| | T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity | Q24805470 |
| | In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy | Q28189640 |
| | Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 |
| | Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. | Q34170327 |
| | The role of interleukin 10 in the regulation of allergic immune responses | Q34453932 |
| | IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy | Q34499562 |
| | Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy | Q34580968 |
| | Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa | Q34590830 |
| | Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors | Q34598797 |
| | Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation | Q36369726 |
| | Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression | Q37273245 |
| | Role of interleukin 10 in specific immunotherapy | Q37387064 |
| | Mechanisms of sublingual immunotherapy | Q37502904 |
| | Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma | Q39515670 |
| | Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study | Q39581669 |
| | Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules | Q39684020 |
| | TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling | Q40247872 |
| | Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. | Q40342009 |
| | Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis | Q40486781 |
| | Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. | Q40511372 |
| | Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 |
| | Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. | Q40593688 |
| | Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. | Q40668250 |
| | Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen | Q42972592 |
| | Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells | Q43664749 |
| | FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses | Q44092288 |
| | Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites | Q44290592 |
| | IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy | Q44429951 |
| | Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. | Q44467274 |
| | Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes | Q44902253 |
| | A chimeric human-cat fusion protein blocks cat-induced allergy | Q46483879 |
| | Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children | Q46879563 |
| | Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma | Q46930354 |
| | Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production | Q46961926 |
| | Analysis of gamma4 germline transcription in human B cells | Q47603766 |
| | Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. | Q48016882 |
| | Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease | Q48029520 |
| | Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. | Q48030345 |
| | Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet | Q48897904 |
| | Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. | Q50688601 |
| | Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. | Q51644402 |
| P433 | issue | 9 | |
| P921 | main subject | immunotherapy | Q1427096 |
| | aeroallergen | Q4688176 |
| P304 | page(s) | 1235-1246 | |
| P577 | publication date | 2011-07-15 | |
| P1433 | published in | Clinical & Experimental Allergy | Q5133747 |
| P1476 | title | Mechanisms of immunotherapy to aeroallergens | |
| P478 | volume | 41 | |